↓ Skip to main content

Dove Medical Press

Article Metrics

Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives

Overview of attention for article published in Adolescent Health, Medicine and Therapeutics, November 2017
Altmetric Badge

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
70 Mendeley
Title
Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives
Published in
Adolescent Health, Medicine and Therapeutics, November 2017
DOI 10.2147/ahmt.s112757
Pubmed ID
Authors

Daisy Maria Machado, Alexandre Machado de Sant'Anna Carvalho, Rachel Riera

Abstract

Adolescents are a critical population that is disproportionately impacted by the HIV epidemic. More than 2 million adolescents between the age group of 10 and 19 years are living with HIV, and millions are at risk of infection. HIV risks are considerably higher among girls, especially in high-prevalence settings such as eastern and southern Africa. In addition to girls, there are other vulnerable adolescent subgroups, such as teenagers, who use intravenous (IV) drugs, gay and bisexual boys, transgender youth, male sex workers, and people who fall into more than one of these categories. Pre-exposure prophylaxis (PrEP) is a new intervention for people at high risk for acquiring HIV, with an estimated HIV incidence of >3%. Recent data from trials show evidence of the efficacy of PrEP as a powerful HIV prevention tool in high-risk populations, including men who have sex with men, HIV-1-serodiscordant heterosexual couples, and IV drug users. The reported efficacy in those trials of the daily use of oral tenofovir, alone or in combination with emtricitabine, to prevent HIV infection ranged from 44% to 75% and was heavily dependent on adherence. Despite the proven efficacy of PrEP in adult trials, concerns remain about its feasibility in real-life scenarios due to stigma, cost, and limited clinician experience with PrEP delivery. Recent studies are attempting to expand the inquiry into the efficacy of such HIV prophylaxis approaches in adolescent populations, but there are still many gaps in knowledge, and no country has yet approved it for use with adolescents. The aim of this review was to identify and summarize the evidence from studies on PrEP for adolescents. We have compiled and reviewed published studies focusing on safety, feasibility, adherence to therapeutics, self-perception, and legal issues related to PrEP in people aged between 10 and 24 years.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 70 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 20%
Student > Master 12 17%
Student > Ph. D. Student 11 16%
Unspecified 9 13%
Student > Bachelor 8 11%
Other 16 23%
Readers by discipline Count As %
Medicine and Dentistry 22 31%
Unspecified 13 19%
Social Sciences 12 17%
Nursing and Health Professions 11 16%
Psychology 6 9%
Other 6 9%